Skip to content

Valneva

  • Über uns
    Über uns Advancing vaccines for better lives Mehr lesen
    • Unsere Strategie
    • Unsere Expertise im Bereich der Reisegesundheit
    • Unsere Verantwortung
    • Unser Team
  • Produkte
    Produkte Focusing on vaccines for infectious diseases with major unmet needs Mehr lesen
    • Japanische Enzephalitis-Impfstoff
    • Cholera-Impfstoff
    • COVID-19 Impfstoff
    • Marketing und Vertrieb
    • Produktion und Dienstleistungen
  • F&D
    F&D Dedicated to innovation in vaccine research and development Mehr lesen
    • Pipeline
    • Lyme Borreliose – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access-Richtlinie
    • Wissenschaftliche Publikationen
  • Investoren
    Investoren Mehr lesen
    • Events und Präsentationen
      • Kalender
      • Präsentationen des Unternehmens
    • Financial & Filings
      • Finanzberichte
      • SEC Filings
    • Pressemeldungen
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Vorgeschriebene Informationen
    • Aktieninformation
      • Aktienkurs
      • Analysten
      • Aktionärsstruktur
      • Delisting von der Wiener Börse
    • Hauptversammlungen
      • 2022 Kombinierte Hauptversammlung
      • June 23, 2022 Special Meeting
      • Archiv Hauptversammlungen
    • Videos und Webcasts
    • Häufig gestellte Fragen
    • Kontakt
  • Medien
    Medien Pressemeldungen, Aktuelles und Ressourcen für Medien Mehr lesen
    • Pressemeldungen
    • In den Nachrichten
    • Ressourcen für Medien
    • Medienkontakte
  • Karriere
Kontakt
  • EN
  • FR
  • | DE
Search

Pressemeldungen

December 17, 2008

VIVALIS AND KAKETSUKEN SIGN TWO COMMERCIAL LICENSE AGREEMENTS TO USE THE EBx® PLATFORM FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINES.

December 10, 2008

VIVALIS SECURES IMPORTANT PATENTS COVERING THE USE OF EB66® PLATFORM TO PRODUCE RECOMBINANT VACCINES

November 4, 2008

PRESENTATION AT THE RODMAN & RENSHAW HEALTHCARE CONFERENCE IN NEW YORK OF NOVEMBER 10-11, 2008

October 28, 2008

Accelerating commercial growth in 2008 third quarter Nine-month revenue: €3.6 million (x 3.7) Net cash at September 30, 2008 increases to €22 million

October 7, 2008

VIVALIS AND CSL LIMITED SIGNED A RESEARCH LICENCE AND OPTION OF COMMERCIAL LICENCE AGREEMENT TO MANUFACTURE A THERAPEUTIC PROTEIN WITH THE EBx® PLATFORM

September 23, 2008

VIVALIS SECURES AN IMPORTANT PATENT COVERING ITS EBx® PLATFORM

September 10, 2008

PARTICIPATION AT THE MIDCAP EVENT IN PARIS ON 29 AND 30 SEPTEMBER 2008

August 28, 2008

Results for the 1st half-year in line with VIVALIS targets and strategy A solid commercial dynamic: 4 new license agreements since the beginning of 2008 Enhanced financial strength and visibility with a new €6m grant from Oséo through its new strategic industrial innovation support program

August 13, 2008

VIVALIS: A very dynamic 2nd quarter for licensing Half year cash position of M€ 21.4

July 22, 2008

GeoVax Partners with VIVALIS for Use of its Revolutionary EBx® Technology to Manufacture its MVA HIV/AIDS Vaccine

  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50

Valneva

  • Über uns
  • Produkte
  • F&D
  • Investoren
  • Medien
  • Karriere
Weitere Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Kontakt
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT